To learn more, please call our Research Department at (513) 936-5388 or (888) 649-4800. Or email abradley@ohcmail.com or jmcguire@ohcmail.com
- NEOADJUVANT
- Study number:
- BRE 133 SCRI
- Protocol title:
- Phase II Study of Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER2-Negative Breast Cancer
- Status:
- Open
-
- Study number:
- BRE 139 SCRI
- Protocol title:
- Phase II Study of Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2- Positive Locally Advanced Breast Cancer
- Status:
- Open
-
- ADJUVANT
- Study number:
- NSABP B-44 BETH Trial
- Protocol title:
- A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2 Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
- Status:
- Open
-
- Study number:
- BRE 128 BIG 2-06/N063D/EGF106708
- Protocol title:
- ALTTO aka Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation: A Randomized, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, their Sequence and their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
- Status:
- Open
-
- Study number:
- BRE 145 SCRI
- Protocol title:
- Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs AC Followed by Paclitaxel in Patients with Triple-Negative Early Breast Cancer
- Status:
- Open
-
- Study number:
- BRE 163 B-46-I/07132 USO/NSABP
- Protocol title:
- Phase III Clinical Trial Comparing the Combination of TC Plus Bevacixumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative Early Breast Cancer
- Status:
- Open
-
- LOCALLY ADVANCED/METASTATIC, FIRST LINE, HER2-
- Study number:
- BRE 154 SCRI
- Protocol title:
- A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab+/- Everolimus as First-Line Chemotherapy for Patients with HER2-Negative Metastatic Breast Cancer (MBC)
- Status:
- Open
-
-
- METASTATIC, FIRST LINE, HER2+
- Study number:
- BRE 132 TOC4129g/WO20698 Genentech, Inc.
- Protocol title:
- A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzamab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2 Positive Metastatic Breast Cancer (CLEOPATRA)
- Status:
- Open
-
- METASTATIC, FIRST OR SECOND LINE, HER2+
- Study number:
- BRE 140 LPT111111 GlaxoSmithKline
- Protocol title:
- A Single-arm, Multicenter Phase II Study to Evaluate the Combination of Weekly Nanoparticle Albumin-bound Paclitaxel (nab-Paclitaxel or Abraxane) and Lapatinib (TYKERB) in Women who have Received No More Than One Prior Chemotherapeutic Regimen in the Treatment of Erb/2 Overexpressing Metastatic Breast Cancer.
- Status:
- Open
-
- HORMONAL
- Study number:
- BRE 144 SNDX-275-0301 Syndax Pharmaceuticals, Inc.
- Protocol title:
- A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane with or without SNDX-275 in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment with a Non-Steroidal Aromatase Inhibitor
- Status:
- Open
-
- METASTATIC OBSERVATIONAL
- Study number:
- BRE 150 AVF4349n Genentech, Inc.
- Protocol title:
- An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer
- Status:
- Open
-
- ONCOTYPE DX ASSAY
- Study number:
- TAILORx PACCT-1 CTSU
- Protocol title:
- Program for the Assessment of Clinical Cancer Tests Trial Assigning Individualized Options for Treatment
- Status:
- Open
-
- RADIATION
- Study number:
- NSABP B-39
- Protocol title:
- A Randomized Phase 3 Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women w/Stage 0,I or II Breast Cancer
- Status:
- Open